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Abstract
Microglial activation plays an integral role in the development and course of neurodegeneration. Although neuro-
peptides such as bradykinin (BK), somatostatin (SST), and endothelin (ET) are known to be important mediators of
inflammation in the periphery, evidence of a similar function in brain is scarce. Using immunocytochemistry, we
demonstrate the expression of receptors for BK (B1, B2 subtypes), ET (ETA, ETB subtypes) and SST (SST 2, 3, 4 sub-
types) in primary microglia and microglial cell lines. Exposure of BV2 and N9, as well as primary microglial cells to
BK or SST increased Ab uptake in a concentration-dependent manner, whereas endothelin decreased Ab uptake.
This was caused by increased phagocytosis of Ab since the rate of intracellular Ab degradation remained unaf-
fected. All neuropeptides increased chemotactic activity of microglia. In addition, BK reduced Ab-induced expres-
sion of proinflammatory genes including iNOS and COX-2. ET decreased the Ab-induced expression of monocyte
chemoattractant protein 1 and interleukin-6. These results suggest that neuropeptides play an important role in
chemotaxis and Ab clearance and modulate the brain’s response to neuroinflammatory processes.
Background
Besides the well described pathological hallmarks, the
deposition of the amyloid b peptide (Ab) in fibrillar pla-
ques and neurofibrillar tangles of tau protein, neuroin-
flammation has a prominent role during Alzheimer
disease (AD) [1]. This is expressed by activated micro-
glia and reactive astrocytes localized to amyloid plaques,
and the release of biochemical markers, like cytokines,
chemokines and nitric oxide, that are found to be
increased in the brains of patients with AD[2]. Micro-
glia, the main immune effector of the brain, are able to
migrate to sites of Ab deposition and to eliminate Ab
by phagocytosis upon activation by multiple receptors
amongst the toll-like receptors (TLR2, TLR4), scavenger
receptor A and CD36.
It is known that certain neuropeptides decline during
aging before the onset of AD [3,4]. Neuropeptides
belong to a family of signalling molecules released by
neurons acting on cell surface receptors. Their role in
inflammation has been widely studied in peripheral tis-
sues [5,6], but their particular function on glial cells has
not been studied in detail so far. There is growing evi-
dence that neuropeptides are able to alter neurodegen-
erative processes during AD [7-10]. Strikingly, brain
regions like the hippocampus and the cortex that are
affected early during AD, are also the regions where
neuropeptides like bradykinin and somatostatin, as well
as their receptors, are prominently present [11-13].
Somatostains are cyclic peptides that are widely
expressed throughout the brain where they act as neuro-
modulators [14]. Five G protein-coupled somatostatin
receptors have been described (SSTR1-5), which are
expressed in distinct yet overlapping patterns within the
brain [15]. Of note, two of them, SSTR2 and SSTR4, are
expressed in the hippocampus and cortex [16]. In AD,
elimination of SST from the cortex and hippocampus is
correlated to reduced cognitive function and memory
impairment [10,17]. In addition, SSTRs show marked
depletion in the AD brain [18-20].
Bradykinin (BK) is a short-lived nonapeptide generated
from the kininogen precursors that is upregulated after
lesions in the CNS [21]. Because of its attenuating effect
on the secretion of pro-inflammatory cytokines from
microglia BK has anti-inflammatory and thereby neuro-
protective properties [21]. Like somatostatin, bradykinin
binds to G protein-coupled receptor at the cell surface.
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Two subtypes of bradykinin receptor, B1 and B2, have
been characterized so far. The expression of B2 bradyki-
nin receptors has been confirmed in the brain stem,
basal nuclei and cerebral cortex, whereas B1 bradykinin
receptors are present in the entorhinal cortex, dentate
gyrus, and pyramidal neurons of the hippocampus.
Besides neurons and astrocytes, primary microglia have
been shown to express BK receptors [22].
Another prominent neuropeptide system in the brain
is the endothelin (ET) system. Endothelins are 21 amino
acid long cyclic peptides. Currently there are three
described isoforms (endothelin 1-3), that derive from
precursor proteins by proteolytic processing [23]. They
signal through two major receptor subtypes known as
ETA and ETB receptors belonging to the superfamily of
G-protein coupled receptor [23]. ET-1, ET-3 as well as
ET receptors are expressed in glial and neuronal cells
[23]. During AD it has been observed that endothelin-1
levels are decreased in the cerebrospinal fluid of AD
patients [9] and its expression has been found to be ele-
vated in frontal and occipital cortex in AD [7].
Since there are multiple indications that suggest an
important role for neuropeptides in inflammation in
general and in particular during the chronic inflamma-
tory processes of AD, we investigated the impact of
these signaling molecules on inflammatory core func-
tions of microglial cells.
Methods
Primary microglial cell culture and microglial cells lines
Primary microglial murine cell cultures were prepared as
previously described in detail (Hanisch et al., 2004).
Briefly, mixed neuronal cultures were prepared from
newborn mice and cultured in DMEM supplemented
with 10% FCS and 100 U ml-1 penicillin/streptomycin.
Microglial cells were harvested by shake-off after 10-14
days of primary cultivation. Primary rat microglial cul-
tures were obtained from the whole brain of newborn
Wistar rats at 0-24 h of age. Mixed glial cells were cul-
tured in High glucose (4.5 mg/ml) DMEM, supplemen-
ted with 10% FCS, 0.2 mM L-glutamine, 0.1 mg/ml
streptomycin, and 0.2 U/ml penicillin was used as the
culture medium. After 12 days, to isolate microglia, cells
were shaken at 200 rpm for 1 h. The medium contain-
ing detached microglia was collected and the isolated
microglia were reseeded and allowed to settle for 24 h
[24]. BV2 and N9 cell lines were mantained in IMDM
supplemented with 5% FCS and 100 U ml-1 penicillin/
streptomycin.
Phagocytosis of FAM-labeled Ab1-42
Microglial phagocytosis of aggregated FAM-labeled
Ab1-42 (FAM-Ab) (Anaspec) was measured by plate
based assay after incubation of Ab at 37°C for three
days. Cells were plated at 50000 cells in 100 μl in black
96 well plates. After 1 h Ab was added to a final con-
centration of 500 nM and incubated for up to 4 h.
Finally, the Ab-containing medium was removed and
extracellular Ab was quenched with 100 μl 0.2% trypan
blue in PBS pH 4.4 for 1 min. After aspiration fluores-
cence was measured at 485 nm excitation/535 nm emis-
sion using a Infinite 200 reader (Tecan). To normalize
for cell numbers 100 μl 50 μg/ml Hoechst Dye 33342 in
PBS was added, incubated for 30 min and the fluores-
cence measured at 360 nm excitation/465 nm emission.
Additionally, microglial Ab phagocytosis was verified by
confocal microscopy. Confocal microscopy was per-
formed using a BX61 microscope equipped with a disc
spinning unit (Olympus).
Assessment of microglial migration
Transwell 96 well permeable supports, containing 8 μm
pore size polyester membrane, were used. Medium con-
taining 10-9- 10-7 M bradykinin (BK), endothelin-1 (ET)
or somatostatin (SST) was added to the lower chamber,
whereas cells, (106 cells/ml), were added to the top
chamber and incubated for 3 h at 37°C. Cells that
passed through the membrane were harvested from the
lower part of the membrane using trypsin, and stained
with calcein AM dye. The stained trypsinized cells were
transferred to a black plate and read in a plate reader at
485 nm excitation, 520 nm emission.
Immunocytochemistry of neuropeptide receptors
Cells were fixed in 4% paraformaldehyd at room tem-
perature, washed twice with 100 mM HEPES pH 7, incu-
bated in 1 μg/ml FC-block (Calbiochem), permeabilized
with 0,1% Tx-100 in PBS for 10 min and non specific
binding was blocked with 10% goat serum in PBS for 2 h.
Sample were incubated overnight with first antibody in
blocking solution, washed three times with PBS and the
secondary antibody was added for 1 h in 10% goat
serum/PBS. Finally the cells were washed three times in
PBS, once in water and mounted with Immomount
(Thermo) containing 5 μg/ml Hoechst 33342. Confocal
microscopy was performed using BX61 equipped with a
disc spinning unit (Olympus). Images were deconvoluted
using the next neighbor algorithm (Cell^P, Olympus)
Determination of microglial Ab1-42 degradation
BV2 and N9 cells were incubated in a black 96-well
plate (50,000 cells per well) and incubated for 15 h with
bradykinin, endothelin or somatostatin. Then, FAM-
labelled Ab was added. After 30 min, all media were
removed, cells mildly washed with warmed medium and
subsequently fresh medium added for the indicated time
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points (0, 1, 2, 3 or 4 h). At each time-point media were
removed and replaced by 0.2% trypan blue solution for
1 min in room temperature. Fluorescence detection of
FAM-labelled Ab1-42 was performed as described above.
In order to confirm that cells were plated equally, cells
were stained with Hoechst 33342.
Western blot
BV2 cells were seeded onto a 6-well plate at a concen-
tration of 2 × 106 cells per well and incubated in full
medium for one hour. Then, medium was replaced by
serum-free medium (SFM) in the absence or presence of
the respective neuropeptide. After 15 h incubation, the
cells were added with SFM or Ab1-42 (at final concen-
tration of 0.5 μM) and incubated for additional 4 h.
After removal of SFM, cells were lysed in lysis buffer
(20 mM Tris-Hcl pH 7.5, 0.5 mM EDTA, 0.5% Triton
X-100 and 5 μM sodium vanadate) in the presence of
protease inhibitors. Protein concentration was deter-
mined by bicinchoninic acid (BCA) assay kit (Thermo).
Cell lysates were separated in 7.5% SDS-PAGE and
blotted onto a nitrocellulose membrane (Biorad). Mem-
branes were blocked for 90 min with 4% BSA and incu-
bated overnight at 4°C with anti-NEP antibody (1:4000)
(Abcam) or anti-IDE antibody (1:4000) (Calbiochem).
After washing membranes were incubated for 90 min
with the HRP-conjugated secondary antibody. Immunor-
eactivity was detected using enhanced chemilumines-
cence (Millipore) solution followed by exposure to X-ray
film (Fuji medical X-ray film, FujiFilm). Semi-quantita-
tive analysis was carried out using a computerized
image analysis system (EZ Quant - Gel 2.2, EZQuant
Biology Software Solutions). Protein load was normal-
ized detecting b-actin (1:4000, Sigma).
Real-Time Reverse Transcription-Polymerase Chain
Reaction
Total RNA was prepared from the cells using RNeasy
mini kit (Qiagen) and reversed transcribed (RT) into
complementary DNA using high capacity cDNA reverse
transcription kit (Applied Biosystems) according to the
manufacturer’s instructions. Real time qPCR was
performed on a StepOnePlus Real-Time PCR System
(Applied Biosystems) using TaqMan gene expression
assay (Applied Biosystems). PCR was carried out in 20
μl with 1 μl of the RT product corresponding to 40 ng
of total RNA, 0.2 μM of each primer and 10 μl of the
master mix with the following temperature profile: 95°C
for 10 min and 40 cycles of 95°C for 15 s and 60°C for
1 min. Amplification specificity was verified by melting
curve analysis. mRNA expression values were normal-
ized to the level of GAPDH expression. For primer
details see Table 1.
Statistical analysis
The immunohistochemical and densitometric data and
were analyzed by 1-way, 2-way ANOVA and Tukey’s
post hoc test (GraphPad Prism 5 or SPSS 17).
Results
In order to assess whether neuropeptides are involved in
the regulation of microglial functions, we first assessed
the presence of the neuropeptide receptors on the cells
lines and murine primary cells utilized in the following
experiments. BV2, N9 and primary murine microglia
expressed the bradykinin receptors 1 and 2, the endothe-
lin receptor A and B as well as the somatostatin receptors
2,3 and 4 (Figure 1). These immunocytochemical experi-
ments document that indeed all the above described neu-
ropeptide receptors can be detected on the microglial cell
surface and thus may be involved in mediating the modu-
lating effects on Ab1-42 phagocytosis and migration
described below.
Microglial Ab1-42 phagocytosis was assessed in two
microglial cell lines, BV2 and N9 cells as well as primary
rat microglia which were incubated with either bradyki-
nin, endothelin or somatostatin for 15 h and subse-
quently exposed to aggregated and FAM-labelled Ab1-42.
While concentrations of 10-9-10-7 M of bradykinin and
somatostatin increased Ab1-42 phagocytosis concentra-
tion-dependently, endothelin showed the opposite effect
(Figure 2). There was no principle difference in quantity
of quality regarding the observed effects in microglial cell
lines compared to primary rat microglia, suggesting that
neuropeptide effects can be studied reliably in the two
immortalized cell lines which were subsequently used.
Principally, the observed effects of neuropeptides on
microglial Ab1-42 uptake after 4 h could also have
resulted from an impairment of Ab1-42 degradation
within microglia instead of an increase of phagocytosis.
We therefore tested whether neuropeptides would influ-
ence the Ab1-42 content of microglia over time after an
initial short exposure of cells to the peptide for only
30 min. Importantly, microglial cells did phagocyte Ab1-
42 within the first 30 min. However, neither bradykinin,
endothelin nor somatostatin affected the microglial Ab
content which showed a progressive decline over 4 h,
consistent with the hypothesis of an unaffected intracel-
lular degradation (Figure 3). None of the neuropeptides
accelerated the decomposition of Ab1-42 within micro-
glia. Together, these experiments validate that neuro-
peptides positively modulate the phagocytosis of Ab but
do not affect its intracellular degradation. Next it was
analyzed whether the observed modulation of Ab1-42
phagocytosis was preserved when cells were simulta-
neously pre-exposed to an immune challenge. Therefore,
BV2 and N9 cells were incubated for 15 h either with
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Figure 1 Immunocytochemical analysis of neuropeptides receptors expression. BV2, N9, and murine primary microglia cells were
immunostained with specific primary antibodies against bradykinin receptors 1 and 2 (B1R, B2R), endothelin A receptor (ETAR), endothelin B
receptor (ETBR), somatostatin receptors 2,3,4 (SSTR2-4). Nuclei were visualized using Hoechst 33342.
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lipopolysaccharide (LPS) alone (0.1 μg/ml) or together
with bradykinin, endothelin or somatostatin. LPS stimu-
lation alone increased the phagocytosis of Ab1-42
(Figure 4). In contrast to the previously observed stimu-
latory effect of bradykinin, costimulation of microglial
cells with LPS lead to a concentration-dependent
decrease of bradykinin stimulated Ab1-42 phagocytosis
(Figure 4A). LPS also abolished the attenuating effect of
endothelin or the enhancing modulation of somatostatin
that were observed under non-inflammatory conditions.
However, all neuropeptides impaired the LPS-induced
increase of Ab1-42 phagocytosis in microglial cells.
Nevertheless, the possible effect of neuropeptides on
the expression of two major Ab degrading activities,
namely, the insulin degrading enzyme (IDE) and nepryli-
sin (NEP), was investigated under control conditions
and in the presence of Ab1-42 (Figure 5). While IDE was
not found to be influenced by any of the conditions
investigated, bradykinin increased the NEP under con-
trol conditions (Figure 5B). This effect, however, was
abolished when cells were coincubated with Ab1-42.
While phagocytosis of Ab was differentially regulated by
neuropeptides, all neuropeptides investigated increased
the capacity of microglia to migrate in a more or less con-
centration-dependent fashion (Figure 6), reaching indeed
very strong effects already at the lowest concentrations.
To assess whether Ab1-42-induced inflammatory gene
transcription is being influenced by neuropeptides
Figure 2 Neuropeptides modulate microglial Ab1-42 phagocytosis. FAM-Ab1-42 phagocytosis was examined in BV2 cells (A, D, G), N9 cells (B,
E, H) and primary rat microglia (C, F, I). Cells were incubated for 15 h with bradykinin (BK) (A-C), endothelin (ET) (D-F) or somatostatin (SST) (G-I)
at concentrations of 10-9-10-7 M. Thereafter, 0.5 μM of FAM-labelled Ab was added and phagocytosis assessed after 4 h. (n = 4 +/- SEM; one-way
ANOVA followed by Tukey’s post test, * P < 0.05 vs. control, ** P < 0.01 vs. control. *** P < 0.001 vs. control).
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Ab1-42-stimulated microglial BV2 and N9 cells were incu-
bated with either bradykinin, somatostatin or endothelin.
While exposure of cells to Ab1-42 alone constantly
decreased the expression of cyclooxygenase-1, all other
targets investigated including cyclooxygenase-2, tumor
necrosis factor-a, interleukin-1b, interleukin-6, inducible
nitric oxide synthase (iNOS), monocyte chemotactic pro-
tein-1 and macrophage inflammatory protein-1a were
robustly increased (Figure 7). Of the latter, only a few tar-
gets were negatively regulated by neuropeptides. Thus,
bradykinin reduced iNOS gene transcription in N9 cells
(Figure 7A), whereas this phenomenon did not reach the
Figure 3 Microglial Ab1-42 degradation is not affected by neuropeptides. BV2 and N9 cells were incubated for 15 h with bradykinin (BK) (A,
B) or endothelin (ET) (C, D) or somatostatin (SST) (E, F). Then, FAM-labelled Ab was added and phagocytosis of Ab1-42 was allowed for 30 min.
Thereafter all media were removed and fresh medium was added for the indicated time periods. In order to confirm that cells were plated
equally, cells were stained with Hoechst 33342 (n = 4 +/- SEM).
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level of statistical significance in BV2 cells. In BV2 cells
however, endothelin decreased IL-6 and MCP-1 gene
transcription (Figure 7B), a results which was not repro-
duced in N9 microglial cells. Somatostatin did not affect
inflammatory gene transcription of the above targets. In
summary this analysis may indicate that the analyzed
neuropeptides are no major regulators of inflammatory
gene transcription and hence the observed effects on
Ab1-42 phagocytosis and migration are not influenced by
inflammatory mediators.
Discussion
Microglial cells represent the brain’s innate immune sys-
tem and are actively involved in maintaining parenchymal
homeostasis through active tissue scanning and removal of
debris by phagocytosis [25]. In neurodegenerative diseases,
Figure 4 Immunostimulation with LPS affects neuropeptide regulation of microglial Ab1-42 phagocytosis. BV2 (A, C, E) and N9 cells (B, D,
F) were incubated for 15 h with LPS alone (0.1 μg/ml) or in the presence of bradykinin (BK) (A, B), endothelin (ET) (C, D) or somatostatin (SST) (E,
F) at concentrations of 10-9-10-7 M. Afterwards cells were incubated with FAM-Ab1-42 for 4 h and the amount of phagocytosed FAM-Ab1-42 was
measured spectrometrically and normalized to untreated control cells (n = 3 +/- SEM; one-way ANOVA followed by Tukey’s post test, ^ P < 0.05
vs. control, ^^^ P < 0.001 vs. control. * P < 0.05 vs. LPS ** P < 0.01 vs. LPS. *** P < 0.001 vs. LPS).
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Figure 5 Expression of neprilysin (NEP) and insulin-degrading enzyme (IDE) in BV2 cells. Cells were incubated with bradykinin (BK) (A, B),
somatostatin (SST) (C, D) or endothelin (ET) (E, F) at concentrations of 10-7 M each. Then, Ab1-42 (0.5 μM) was added and the cells incubated for
additional 4 h. Western blot analysis was performed using whole cell lysates and antibodies directed against NEP (B, D, F), IDE (A, C, E) and
b-actin. Representative gels of three independent experiments (n = 3 +/- SEM; one-way ANOVA followed by Tukey’s post test, *P < 0.05).
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activation of microglia leads to an alteration of these phy-
siological functions, which in turn may contribute to dis-
ease progression and neuronal death. Next to cytokines
and chemokines, neurotransmitters including norepi-
nephrine, glutamate and acetylcholine can modulate the
inflammatory action of microglia and influence their func-
tions [26,27]. Thus, neuronal activity and release of these
factors may determine the activation status and finally the
conditions whether microglia turn towards a beneficial or
detrimental phenotype. In AD, various neurotransmitter
systems are compromised and may thereby impair micro-
glial functions in response to Ab deposition including
phagocytosis and migration [28]. Impaired microglial
phagocytosis of Ab, however, may directly contribute to
disease progression and neuronal dysfunction.
The presence of neuropeptide receptors on microglia
suggests that these factors may be actively involved in the
regulation of microglial functions [22,29,30]. After con-
firming the expression of bradykinin, endothelin and
somatostatin receptors on primary murine microglia as
well as on the microglial cell lines, the capacity of micro-
glia to phagocyte fibrillar Ab after preincubation with
increasing concentrations of either one of the respective
neuropeptides was studied. Of note, the overall levels of
the peptides are low in the normal rodent and human
brain. In particular, the basal levels of endothelins have
Figure 6 Neuropeptides positively regulate microglial migration. The effect of neuropeptides on migration of BV2 (A, C, E) and N9 (B, D, F)
cells were analyzed in a transwell assay after 3 h incubation with increasing concentrations of BK (A, B), SST (C, D) or ET (E, F). Cells that passed
through the membrane were harvested, stained with calcein AM dye, and fluorescence was read at 485 nm excitation and 520 nm emission.
(n = 4 +/- SEM; one-way ANOVA followed by Tukey’s post test. ** P < 0.01 vs. control. *** P < 0.001 vs. control.). Similar results were obtained in
2 additional experiments for BV2 and N9 cells.
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Figure 7 Effect of neuropeptides on inflammatory genes expression. BV2 (left column) and N9 (right column) cells were incubated with
bradykinin (BK) (A), endothelin (ET) (B) or somatostatin (SST) (C) for 15 h at the concentration of 10-7 M. Then, microglia were exposed to Ab1-42
(1 μM) and cells harvested after 4 h. At the end of the experiment, total RNA was extracted and reverse transcribed. Finally, Real time qPCR was
performed. mRNA expression was normalized to GAPDH. Similar results were obtained in additional experiment for BV2 and N9 cells (n = 2
+/-SEM performed in triplicates; two-way ANOVA followed by Bonferroni multiple comparison. * P < 0.05 vs. control. ** P < 0.01 vs. control.
*** P < 0.001 vs. control. ^ P < 0.05 vs. Ab, ^^ P < 0.01 vs. Ab).
Fleisher-Berkovich et al. Journal of Neuroinflammation 2010, 7:61
http://www.jneuroinflammation.com/content/7/1/61
Page 10 of 13
been found to be 0.37 × 10-9 M in human cerebrospinal
fluid [31], but undergo a massive upregulation upon
brain injury [32,33]. Further, the release of somatostatin
from incubated rat hypothalamus has been determined
to be 3 × 10-9 M [34]. Finally, the exact levels of brain
bradykinin are unknown. Nevertheless, the literature is
unanimous in that bradykinin, used at 10-7 M and higher,
stimulates glial inflammation [35]. We therefore used
these peptides in the range from 10-9 to 10-7 M, corre-
sponding to physiological as well as 10 to 100 fold
increased concentrations.
While bradykinin and somatostatin increased micro-
glial Ab phagocytosis in a concentration-dependent
manner, endothelin showed the opposite action, suggest-
ing a distinct regulation of Ab uptake by neuropeptides.
Importantly, none of the investigated peptides altered
the intracellular degradation of Ab thus confirming that
the observed differences are solely due to increased
uptake by microglia. While there is no previous infor-
mation on the modulation of microglial phagocytosis by
these substances, in general a positive regulation of pha-
gocytosis by bradykinin had been reported in peripheral
leucocytes after intravenous application of this neuro-
peptide in rabbits [36]. In contrast, somatostatin had
been found to suppress the phagocytic capacity of
macrophages for Leishmania major parasites [37].
Together, these data suggest that the neuropeptides do
not generally up- or downregulate phagocytosis, but the
later action strongly involves target-specific mechanisms.
Since somatostatin is reduced in AD brain and in CSF
of AD patients [38,39], one can speculate that this reduc-
tion contributes to Ab deposition in the AD brain
through impaired microglial phagocytosis along with the
previously described negative influence on Ab degrada-
tion by neprilysin [40]. Likewise, the increase of endothe-
lin expression observed in AD frontal and occipital
cortex could compromise the effective clearance of the
brain from Ab by reducing microglial phagocytosis [7].
Interestingly, immunostimulation of microglia with
bacterial lipopolysaccharide (LPS) almost completely
abolished the regulatory effects of neuropeptides on
microglial Ab phagocytosis. Systemic bacterial infection
has been reported to aggravate the clinical symptoms of
AD patients [41], a phenomenon which may be explained
by several mechanisms. However, extrapolating the find-
ings of this study, it can be hypothesized that an addi-
tional immune challenge, in this case by LPS, leads to the
reduction of beneficial microglial functions evoked neu-
ropeptides such as bradykinin and somatostatin -even if
those are decreased in AD brains as stated above, since
the increased Ab uptake observed in response to these
neuropeptides is compromised by pre-exposure to LPS.
Since in the CNS migration of microglial towards
inflammatory lesion sites plays an important role in
resolving neuroinflammation and restoring local home-
ostasis, the effect of the three neuropeptides on migra-
tion were investigated. In contrast to the divergent
effects on phagocytosis, all three neuropeptides collec-
tively increased microglial migration. Bradykinin has
been shown before to stimulate microglial migration in
a concentration- and time-dependent manner and seems
to involve the bradykinin 1 receptor [42], however
no positive regulation on migration in general, but inhi-
bition of Leishmania major promastigote-induced
macrophage migration had been reported previously for
somatostatin [43].
Once phagocyted, microglial cells are able to degrade
Ab fibrils [44]. Several enzymatic systems have been
described to be involved in this process, but the detailed
mechanisms underlying phagolysosomal decomposition
have not been elucidated. Both neprilysin (NEP) and
insulin degrading enzyme (IDE) play the pivotal role for
Ab degradation in the brain [45]. While NEP is presum-
ably acting within a cell, IDE is also being secreted and
involved in extracellular Ab degradation [46]. To test
whether neuropeptides are also influencing the genera-
tion of these systems, in the absence or presence of Ab,
microglial expression of these enzymes was detected. In
the case of Bradykinin there was a trend to increased
levels of IDE, however this effect did not reach the level
of statistical significance. Of note, the same neuropep-
tide increased microglial NEP levels, an effect that dis-
appeared when cells were challenged with Ab. The
latter phenomenon suggests that Ab has a negative reg-
ulatory function on NEP levels. The two other neuro-
peptides tested did not influence either NEP or IDE
levels suggesting that this effect is specific for bradyki-
nin. Since previous studies suggested an anti-inflamma-
tory role of neuropeptides, in particular of bradykinin
[47], we analyzed the regulation of inflammatory gene
mRNA levels in response to Ab stimulation and neuro-
peptide incubation. Under all conditions, incubation of
microglial cells with Ab strongly upregulated inflamma-
tory gene transcription including tumor necrosis factor
a, interleukin-1b, interleukin-6, inducible nitric oxide
synthase (iNOS), monocyte chemoattractant protein-1,
macrophage inflammatory protein-1a, cyclooxygenase-2,
while cycloxygenase-1 was downregulated by the identi-
cal treatment. However, a significant decrease of inflam-
matory mRNA levels was only observed in N9 cells,
where bradykinin decreased iNOS and in the BV2 cell
line, where IL-6 and MCP-1 were negatively controlled
by endothelin. It seems possible that the chosen time
point have not allowed for the detection of stronger
regulatory effects, however, it still suggests that the
observed neuropeptide regulation of microglia function
is a direct effect and not secondary to chemo- or cyto-
kine regulation.
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Conclusion
Together our data suggest that neuropeptides may be cri-
tically involved in the modulation and guidance of micro-
glial functions relevant for AD. Since these neuropeptides
are generated and secreted from neurons, the latter may
be intimately involved in immune cell regulation and
modification of the neuroinflammatory component of
AD. Future studies are needed to unravel the intracellular
signaling pathways involved and to verify these data in
appropriate animal models.
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